title: Altered T Lymphocyte Proliferation upon Lipopolysaccharide Challenge Ex Vivo.
abstract: BACKGROUND
  Sepsis is characterized by the development of adaptive immune cell alterations, which intensity and duration are associated with increased risk of health-care associated infections and mortality. However, pathophysiological mechanisms leading to such lymphocyte dysfunctions are not completely understood, although both intrinsic lymphocyte alterations and antigen-presenting cells (APCs) dysfunctions are most likely involved.
  
  
  METHODS
  The aim of the current study was to evaluate whether lipopolysaccharide (LPS, mimicking initial Gram negative bacterial challenge) could directly impact lymphocyte function after sepsis. Therefore, we explored ex-vivo the effect of LPS priming on human T lymphocyte proliferation induced by different stimuli.
  
  
  RESULTS
  We showed that LPS priming of PBMCs reduced T cell proliferative response and altered IFNγ secretion after stimulation with OKT3 but not with phytohaemagglutinin or anti-CD2/CD3/CD28-coated beads stimulations. Interestingly only LPS priming of monocytes led to decreased T cell proliferative response as opposed to LPS priming of lymphocytes. Importantly, LPS priming was associated with reduced expression of HLA-DR, CD86 and CD64 on monocytes but not with the modification of CD3, CTLA4, PD-1 and CD28 expressions on lymphocytes. Finally, IFNγ stimulation restored monocytes accessory functions and T cell proliferative response to OKT3.
  
  
  CONCLUSIONS
  We conclude that LPS priming does not directly impact lymphocyte functions but reduces APC's capacity to activate T cells. This recapitulates ex vivo indirect mechanisms participating in sepsis-induced lymphocyte alterations and suggests that monocyte-targeting immunoadjuvant therapies in sepsis may also help to improve adaptive immune dysfunctions. Direct mechanisms impacting lymphocytes being also at play during sepsis, the respective parts of direct versus indirect sepsis-induced lymphocyte alterations remain to be evaluated in clinic.
authors.affiliation: BioMérieux, Joint Research Unit, Hospices Civils de Lyon-bioMérieux, Hôpital Edouard Herriot, Lyon, France.
authors.forename: Fanny
authors.initials: F
authors.lastname: Poujol
authors.affiliation: BioMérieux, Joint Research Unit, Hospices Civils de Lyon-bioMérieux, Hôpital Edouard Herriot, Lyon, France.|Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Monneret
authors.affiliation: BioMérieux, Joint Research Unit, Hospices Civils de Lyon-bioMérieux, Hôpital Edouard Herriot, Lyon, France.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Pachot
authors.affiliation: BioMérieux, Joint Research Unit, Hospices Civils de Lyon-bioMérieux, Hôpital Edouard Herriot, Lyon, France.|Anesthesiology and Intensive care department, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Textoris
authors.affiliation: BioMérieux, Joint Research Unit, Hospices Civils de Lyon-bioMérieux, Hôpital Edouard Herriot, Lyon, France.|Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.
authors.forename: Fabienne
authors.initials: F
authors.lastname: Venet
mesh_terms: D000328:Adult; D000368:Aged; D000938:Antigen-Presenting Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D055815:Young Adult
chemical_list: D008070:Lipopolysaccharides